

OncoGeneDx: Renal Cancer Panel

Panel Gene List: *BAP1, EPCAM*, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL*

*Testing includes sequencing and deletion/duplication analysis for all genes except *EPCAM* (del/dup only).

Clinical Features:

In the general population, approximately 1.6% of individuals will develop renal cancer in their lifetime.¹ Most cases of renal cancers develop sporadically. It has been estimated that approximately 3-5% of renal cancer cases are due to a hereditary predisposition.^{2,3} The features of a personal and/or family history of cancer that are suggestive of a hereditary cancer predisposition include: young ages at diagnosis, multiple primary cancers in a single individual, diagnosis of a cancer type that is not common in general population (such as renal cancer), and several relatives affected with cancer spanning multiple generations.

Hereditary renal cancer has long been described in association with several phenotypically distinct syndromes. These include von Hippel-Lindau disease (*VHL*), hereditary papillary renal cancer (*MET*), Birt-Hogg-Dubé syndrome (*FLCN*), hereditary leiomyomatosis and renal cell carcinoma (*FH*) and tuberous sclerosis complex (*TSC1, TSC2*). Pathogenic variants in these six aforementioned genes account for a significant portion of hereditary renal cancer and have been well described in the literature. In addition, several other well described syndromes include a risk of renal cancer as a minor feature. These include Lynch syndrome (*MLH1, MSH2, MSH6, PMS2, EPCAM*), Cowden syndrome (*PTEN*), Li-Fraumeni syndrome (*TP53*) and hereditary paraganglioma/pheochromocytoma syndrome (*SDHB, SDHC, SDHD*). Management guidelines are available for these genes.

Pathogenic variants in newer genes, such as *BAP1* and *MITF*, have been identified in families with renal cancer and may increase the risk for other cancers as well. The evidence available to date may be derived from a small number of patients with wide confidence intervals or is based upon an ethnic cohort with one specific variant. Accurate risk assessment may be complicated by the low penetrance of pathogenic variants in these genes and/or ascertainment bias. Since the cancer risks are not yet well defined, no consensus guidelines for medical management are available for these genes.

Inheritance Pattern:

All genes on this panel are associated with an autosomal dominant cancer risk. Some of the genes on this panel are also associated with extremely rare conditions when inherited in an autosomal recessive fashion. The specifics of this inheritance are outlined in the table below.

Test Methods:

Genomic DNA is extracted from the submitted specimen. For skin punch biopsies, fibroblasts are cultured and used for DNA extraction. The DNA is enriched for the complete coding regions and splice junctions of the genes on this panel using a proprietary targeted capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). For *PTEN* nucleotides c.-700 through c.-1300 in the promoter region is also captured. The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons; however, technical limitations and inherent sequence properties effectively reduce this resolution for some genes. Concurrent *MSH2* Exons 1-7 Inversion analysis from NGS data is also performed. For *EPCAM*, deletion/duplication analysis, but not sequencing, is performed. Alternative sequencing or copy number detection methods are used to analyze or confirm regions with inadequate sequence or copy number data by NGS. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

Test Sensitivity:

The clinical sensitivity of sequencing and deletion/duplication analysis of the 18 genes included in the OncoGeneDx Renal Cancer Panel depends in part on the patient's clinical phenotype and family history. In general, the sensitivity is highest for individuals with features suggestive of a hereditary predisposition to cancer as outlined above. DNA sequencing will detect nucleotide substitutions and small insertions and deletions, while NGS-CNV analysis, array CGH, or MLPA will detect exon-level deletions and duplications. These methods are expected to be greater than 99% sensitive in detecting pathogenic variants identifiable by sequencing or CNV technology.

Genetic testing using the methods applied at GeneDx is expected to be highly accurate. Normal findings do not rule out the diagnosis of a genetic disorder since some genetic abnormalities may be undetectable by this test. The methods used cannot reliably detect deletions of 20bp to 250bp in size, or insertions of 10bp to 250 bp in size. Sequencing cannot detect low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect mosaicism and cannot identify balanced chromosome aberrations. Rarely, incidental findings of large chromosomal rearrangements outside the gene of interest may be identified. Regions of certain genes have inherent sequence properties (for example: repeat, homology, or pseudogene regions, high GC content, rare polymorphisms) that yield suboptimal data, potentially impairing accuracy of the results. False negatives may also occur in the setting of bone marrow transplantation, recent blood transfusion, or suboptimal DNA quality. In

individuals with active or chronic hematologic neoplasms or conditions, there is a possibility that testing may detect an acquired somatic variant, resulting in a false positive result. As the ability to detect genetic variants and naming conventions can differ among laboratories, rare false negative results may occur when no positive control is provided for testing of a specific variant identified at another laboratory. The chance of a false positive or false negative result due to laboratory errors incurred during any phase of testing cannot be completely excluded. Interpretations are made with the assumption that any clinical information provided, including family relationships, are accurate. Consultation with a genetics professional is recommended for interpretation of results.

Gene	Protein	Inheritance	Disease Associations
<i>BAP1</i> ^{4,5}	UBIQUITIN CARBOXYL-TERMINAL HYDROLASE BAP1	AD	Uveal/cutaneous melanoma, mesothelioma & renal cancer
<i>EPCAM</i> ⁶⁻¹¹	EPITHELIAL CELL ADHESION MOLECULE	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>FH</i> ¹²⁻¹⁶	FUMARATE HYDRATASE, MITOCHONDRIAL	AD	Hereditary leiomyomatosis and renal cell cancer (HLRCC): Renal cancer (type II papillary), leiomyomas, pheochromocytoma, paraganglioma
		AR	Fumarate hydratase deficiency
<i>FLCN</i> ¹⁷⁻²¹	FOLLICULIN	AD	Birt-Hogg-Dubé syndrome (BHD): Renal cancer
<i>MET</i> ²²⁻²⁵	HEPATOCTE GROWTH FACTOR RECEPTOR	AD	Hereditary papillary renal carcinoma (HPRC): Renal cancer (type I papillary)
<i>MITF</i> ²⁶⁻²⁸	MICROPTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR	AD	Renal cancer & melanoma
<i>MLH1</i> ^{6,8-11,29,30}	DNA MISMATCH REPAIR PROTEIN MLH1	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain

Gene	Protein	Inheritance	Disease Associations
			cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MSH2</i> ^{6-11,29,30}	DNA MISMATCH REPAIR PROTEIN MSH2	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MSH6</i> ^{6,8-11,29,30}	DNA MISMATCH REPAIR PROTEIN MSH6	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>PMS2</i> ^{6,8-11,31,32}	MISMATCH REPAIR ENDONUCLEASE PMS2	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>PTEN</i> ^{29,33-36}	PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN	AD	<i>PTEN</i> hamartoma tumor syndrome (PHTS): Breast, thyroid, endometrial, colon, melanoma & renal cancer, gastrointestinal polyps, Lhermitte-Duclos disease
<i>SDHB</i> ³⁷⁻⁴⁰	SUCCINATE DEHYDROGENASE [UBIQUINONE] IRON-SULFUR SUBUNIT, MITOCHONDRIAL	AD	Hereditary paraganglioma/pheochromocytoma (PGL/PCC) syndrome: Paraganglioma, pheochromocytoma, renal cancer, GIST
		AR	Isolated complex II deficiency

Gene	Protein	Inheritance	Disease Associations
<i>SDHC</i> ^{37,38,41-43}	SUCCINATE DEHYDROGENASE CYTOCHROME B560 SUBUNIT, MITOCHONDRIAL	AD	Hereditary paraganglioma/pheochromocytoma (PGL/PCC) syndrome: Paraganglioma, pheochromocytoma, renal cancer, GIST
<i>SDHD</i> ^{37-39,44,45}	SUCCINATE DEHYDROGENASE [UBIQUINONE] CYTOCHROME B SMALL SUBUNIT, MITOCHONDRIAL	AD	Hereditary paraganglioma/pheochromocytoma (PGL/PCC) syndrome: Paraganglioma, pheochromocytoma, renal cancer, GIST, thyroid cancer
		AR	Isolated complex II deficiency
<i>TP53</i> ⁴⁶⁻⁵¹	CELLULAR TUMOR ANTIGEN P53	AD	Li-Fraumeni syndrome (LFS): Breast cancer, sarcoma, brain cancer, hematologic malignancies, adrenocortical carcinoma, among others**
<i>TSC1</i> ⁵²⁻⁵⁴	HAMARTIN	AD	Tuberous sclerosis complex (TSC): Renal cancer/tumors, CNS tumors (subependymal nodules and subependymal giant cell astrocytomas), hamartomatous tumors (cardiac rhabdomyomas and angiomyolipomas)
<i>TSC2</i> ⁵²⁻⁵⁴	TUBERIN	AD	Tuberous sclerosis complex (TSC): Renal cancer/tumors, CNS tumors (subependymal nodules and subependymal giant cell astrocytomas), hamartomatous tumors (cardiac rhabdomyomas and angiomyolipomas)
<i>VHL</i> ⁵⁵⁻⁵⁸	VON HIPPEL-LINDAU DISEASE TUMOR SUPPRESSOR	AD	von Hippel-Lindau (VHL) disease: Renal cancer (clear cell), pancreatic neuroendocrine tumors, hemangioblastoma, pheochromocytoma, endolymphatic sac tumors

Because of evolving and expanding phenotypes, this list of cancer/tumor types is not exhaustive. Gene-specific risk for some of the cancers and other features listed are not well-defined.

** High overall risk of cancer: 75% lifetime risk for males to develop cancer, nearly 100% risk for females.

Abbreviations:

AD – Autosomal Dominant

AR – Autosomal Recessive

CGH – Comparative genomic hybridization

GIST – Gastrointestinal stromal tumor

MLPA – Multiplex ligation-dependent probe amplification

References:

1. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. SEER Cancer Statistics Review, 1975-2012: Lifetime Risk Tables (URL: <http://surveillance.cancer.gov/devcan>) [October 2016 accessed].
2. Rini, B. I., Campbell, S. C. & Rathmell, W. K. Renal cell carcinoma. *Curr. Opin. Oncol.* **18**, 289–296 (2006).
3. Coleman, J. A. & Russo, P. Hereditary and familial kidney cancer. *Curr. Opin. Urol.* **19**, 478–485 (2009).
4. Pilarski, R. et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. *Genes. Chromosomes Cancer* **53**, 177–182 (2014).
5. Rai, K., Pilarski, R., Cebulla, C. M. & Abdel-Rahman, M. H. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. *Clin. Genet.* **89**, 285–294 (2016).
6. Weissman, S. M. et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review. *J. Genet. Couns.* **20**, 5–19 (2011).
7. Li-Chang, H. H. et al. Colorectal cancer in a 9-year-old due to combined EPCAM and MSH2 germline mutations: case report of a unique genotype and immunophenotype. *J. Clin. Pathol.* **66**, 631–633 (2013).
8. Durro, C. A., Holter, S., Sherman, P. M. & Gallinger, S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. *Am. J. Gastroenterol.* **105**, 2449–2456 (2010).
9. Vasen, H. F. et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. *Gastroenterology* **110**, 1020–1027 (1996).
10. Wimmer, K. & Kratz, C. P. Constitutional mismatch repair-deficiency syndrome. *Haematologica* **95**, 699–701 (2010).
11. Win, A. K. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **30**, 958–964 (2012).
12. Menko, F. H. et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. *Fam. Cancer* **13**, 637–644 (2014).
13. Pithukpakorn, M. & Toro, J. R. Hereditary Leiomyomatosis and Renal Cell Cancer. in *GeneReviews®* (eds. Adam, M. P. et al.) (University of Washington, Seattle, 1993).
14. Coughlin, E. M. et al. Molecular analysis and prenatal diagnosis of human fumarase deficiency. *Mol. Genet. Metab.* **63**, 254–262 (1998).
15. Smit, D. L. et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. *Clin. Genet.* **79**, 49–59 (2011).
16. Home - HLRCC Family Alliance. Available at: <http://hlrccinfo.org/>. (Accessed: 18th May 2018).
17. Menko, F. H. et al. Birt-Hogg-Dubé syndrome: diagnosis and management. *Lancet Oncol.* **10**, 1199–1206 (2009).
18. Schmidt, L. S. et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. *Am. J. Hum. Genet.* **76**, 1023–1033 (2005).
19. Toro, J. R. Birt-Hogg-Dubé Syndrome. in *GeneReviews®* (eds. Adam, M. P. et al.) (University of Washington, Seattle, 1993).
20. Toro, J. R. et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. *J. Med. Genet.* **45**, 321–331 (2008).
21. Benusiglio, P. R. et al. Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study. *Orphanet J. Rare Dis.* **9**, 163 (2014).
22. Olivero, M. et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. *Int. J. Cancer* **82**, 640–643 (1999).
23. Lubensky, I. A. et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. *Am. J. Pathol.* **155**, 517–526 (1999).
24. Ornstein, D. K. et al. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. *J. Urol.* **163**, 431–433 (2000).
25. Schmidt, L. S. et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. *J. Urol.* **172**, 1256–1261 (2004).
26. Bertolotto, C. et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature* **480**, 94–98 (2011).
27. Potrony, M. et al. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations. *JAMA Dermatol.* **152**, 405–412 (2016).
28. Ghorzo, P. et al. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. *Pigment Cell Melanoma Res.* **26**, 259–262 (2013).
29. Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* **305**, 2304–2310 (2011).
30. Quehenberger, F., Vasen, H. F. A. & van Houtwelingen, H. C. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J. Med. Genet.* **42**, 491–496 (2005).
31. Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology* **135**, 419–428 (2008).
32. ten Broeke, S. W. et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **33**, 319–325 (2015).
33. Jaspersen, K. W. Genetic testing by cancer site: colon (polyposis syndromes). *Cancer J. Sudbury Mass* **18**, 328–333 (2012).
34. Bubián, V. et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J. Med. Genet.* **50**, 255–263 (2013).
35. Hobert, J. A. & Eng, C. PTEN hamartoma tumor syndrome: an overview. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **11**, 687–694 (2009).

36. Tan, M.-H. et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **18**, 400–407 (2012).
37. Lenders, J. W. M. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J. Clin. Endocrinol. Metab.* **99**, 1915–1942 (2014).
38. Kirmani, S. & Young, W. F. Hereditary Paraganglioma-Pheochromocytoma Syndromes. in *GeneReviews*(®) (eds. Pagon, R. A. et al.) (University of Washington, Seattle, 1993).
39. Neumann, H. P. H. et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. *JAMA* **292**, 943–951 (2004).
40. Welander, J., Söderkvist, P. & Gimm, O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. *Endocr. Relat. Cancer* **18**, R253-276 (2011).
41. Niemann, S. & Müller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. *Nat. Genet.* **26**, 268–270 (2000).
42. Peczkowska, M. et al. Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. *Nat. Clin. Pract. Endocrinol. Metab.* **4**, 111–115 (2008).
43. Miettinen, M. & Lasota, J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. *Int. J. Biochem. Cell Biol.* **53**, 514–519 (2014).
44. Jackson, C. B. et al. Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency. *J. Med. Genet.* **51**, 170–175 (2014).
45. Benn, D. E. et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. *J. Clin. Endocrinol. Metab.* **91**, 827–836 (2006).
46. Pennington, K. P. et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. *Cancer* **119**, 332–338 (2013).
47. Chompret, A. et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. *Br. J. Cancer* **82**, 1932–1937 (2000).
48. Gonzalez, K. D. et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **27**, 1250–1256 (2009).
49. Olivier, M. et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res.* **63**, 6643–6650 (2003).
50. Ruijs, M. W. G. et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. *J. Med. Genet.* **47**, 421–428 (2010).
51. Hisada, M., Garber, J. E., Fung, C. Y., Fraumeni, J. F. & Li, F. P. Multiple primary cancers in families with Li-Fraumeni syndrome. *J. Natl. Cancer Inst.* **90**, 606–611 (1998).
52. Northrup, H., Krueger, D. A. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr. Neurol.* **49**, 243–254 (2013).
53. Krueger, D. A., Northrup, H. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr. Neurol.* **49**, 255–265 (2013).
54. Au, K. S. et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **9**, 88–100 (2007).
55. Frantzen, C., Klasson, T. D., Links, T. P. & Giles, R. H. Von Hippel-Lindau Syndrome. in *GeneReviews*(®) (eds. Pagon, R. A. et al.) (University of Washington, Seattle, 1993).
56. Mannelli, M. et al. Genetics and biology of pheochromocytoma. *Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc.* **115**, 160–165 (2007).
57. Maher, E. R., Neumann, H. P. & Richard, S. von Hippel-Lindau disease: a clinical and scientific review. *Eur. J. Hum. Genet. EJHG* **19**, 617–623 (2011).
58. Lonser, R. R. et al. von Hippel-Lindau disease. *Lancet Lond. Engl.* **361**, 2059–2067 (2003).